Kodiak Sciences Balance Sheet Health
Financial Health criteria checks 6/6
Kodiak Sciences has a total shareholder equity of $265.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $479.4M and $213.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$285.51m |
| Equity | US$265.78m |
| Total liabilities | US$213.59m |
| Total assets | US$479.37m |
Recent financial health updates
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Apr 17
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Dec 29We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Sep 09Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?
May 26We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Jan 04Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Sep 25Recent updates
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Apr 17We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Dec 29We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Sep 09Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?
May 26We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Jan 04Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Sep 25GreenWood Investors - Kodiak Sciences: The Busted Biotech World
Aug 25Kodiak Sciences FQ1 2022 Earnings Preview
Aug 07Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?
May 18Kodiak Sciences: Potential For Comeback After Trial Setback
May 17Kodiak Sciences: KSI-301 Disappoints
Feb 25Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter
Feb 15We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely
Jan 24Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Oct 11Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company
Jul 19Kodiak Sciences EPS in-line
May 10Kodiak Sciences hits the capital raise button; shares dip after hours
Nov 16Kodiak Sciences EPS misses by $0.12
Nov 09Financial Position Analysis
Short Term Liabilities: KOD's short term assets ($289.3M) exceed its short term liabilities ($41.7M).
Long Term Liabilities: KOD's short term assets ($289.3M) exceed its long term liabilities ($171.9M).
Debt to Equity History and Analysis
Debt Level: KOD is debt free.
Reducing Debt: KOD had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KOD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KOD has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 38% each year.